Skip to content
CancerIndex

Publication

Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.

Authors not recorded

Clin Cancer Res2014PMID 24963049PMC4155010stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (4)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 4

Curated evidence

Evidence citing this paper (1)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
24963049
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
FLI1 Fusion1
HCI-2509Ewing SarcomaPredictiveDSupports Sensitivity Response2accepted
EID12516

Preclinical studies demonstrated that the LSD1 inhibitor HCI-2509 reduced proliferation and induced apoptosis in five EWSR1-FLI1 fusion-positive Ewing sarcoma cell lines (A673, TC32, TC71, SK-N-MC, CH… (full text at CIViC)

PMID 24963049 · Sankar et al., 2014 · Open in CIViC

civic